Lung Cancer — Tratamiento en Cuba
Lung cancer is the leading cause of cancer death worldwide. Cuba has developed CIMAvax-EGF®, a groundbreaking therapeutic immunotherapy vaccine that targets epidermal growth factor (EGF) — a protein that lung cancer cells need to grow. At La Pradera International Health Center in Havana, Cuba, our integrative oncology program offers international patients access to CIMAvax-EGF® therapy alongside comprehensive supportive care.
Video del Tratamiento
Más información sobre este programa de tratamiento
Understanding Lung Cancer
Lung cancer begins in the lungs and is broadly classified into two main types. Understanding the type and stage is essential for determining the appropriate treatment approach.
Non-small cell lung cancer (NSCLC) — accounts for about 85% of cases
Small cell lung cancer (SCLC) — more aggressive, spreads quickly
Adenocarcinoma — most common NSCLC subtype
Squamous cell carcinoma — arises in the airways
Large cell carcinoma — less common, grows rapidly
Signs and Symptoms
Lung cancer symptoms often do not appear until the disease is advanced. Early detection significantly improves outcomes:
Persistent cough that worsens over time
Coughing up blood or rust-colored sputum
Chest pain that worsens with breathing or coughing
Shortness of breath or wheezing
Hoarseness or voice changes
Unexplained weight loss and loss of appetite
Fatigue and weakness
Frequent respiratory infections
Diagnosis and Staging
Diagnosis involves imaging, biopsy, and molecular testing to determine the stage and guide treatment.
Chest X-ray and CT scan
Biopsy of lung tissue for definitive diagnosis
Molecular and genetic testing (EGFR, ALK, KRAS)
PET-CT scan for staging and metastasis detection
Stage I–IV classification based on tumor size, lymph node involvement, and spread
CIMAvax-EGF®: Cuban Immunotherapy Innovation
CIMAvax-EGF® is a therapeutic cancer vaccine developed by the Center of Molecular Immunology (CIM) in Havana, Cuba. It is designed to stimulate the immune system to produce antibodies against epidermal growth factor (EGF), a protein that non-small cell lung cancer cells need to grow. More than 5,000 patients worldwide have been treated with CIMAvax-EGF®, with studies indicating prolonged tumor stabilization and improved survival and quality of life.
Therapeutic vaccine targeting the EGF protein
Approved for use in Cuba and several countries
Designed for stage IIIB/IV non-small cell lung cancer
Stimulates the body's own immune system to fight cancer
More than 5,000 patients treated worldwide
Now in clinical trials with the US FDA through Roswell Park collaboration
Cuban Integrative Treatment Approach
Our integrative oncology program combines CIMAvax-EGF® immunotherapy with comprehensive supportive care tailored to each patient.
CIMAvax-EGF® immunotherapy evaluation
Coordination with chemotherapy and radiation protocols
Supportive care for symptom management
Nutritional oncology support
Pain management and quality-of-life therapies
Psychological support and counseling
Patient Eligibility
Our oncology team reviews each patient's complete medical records to determine eligibility for CIMAvax-EGF® therapy.
Confirmed non-small cell lung cancer diagnosis (stage IIIB/IV)
Completed first-line chemotherapy
Pathology reports and staging documentation
Recent imaging (CT, PET-CT) on CD
Current health status and blood work
Ability to travel to Cuba for the treatment duration
Travel to Cuba for Lung Cancer Treatment
Our international patient services team supports patients and families through every step of the journey to Havana.
Medical record review and treatment evaluation before travel
Visa documentation and medical invitation letters
Airport reception at José Martí International Airport, Havana
Multilingual coordinators including English and Spanish speakers
Comfortable accommodation for patients and family
Cost of Treatment in Cuba
Cuban lung cancer treatment with CIMAvax-EGF® is significantly more affordable than equivalent private care — typically 60–80% less than US or European private treatment. Detailed estimates are provided after medical review and treatment plan finalization.
Comience su Viaje hacia la Recuperación
Envíe su historia clínica e informes, y nuestros especialistas evaluarán su caso y recomendarán un plan de tratamiento personalizado.
Solicitar una ConsultaWhatsAppOncología Integrativa
Explorar el programa de tratamiento →
Lung Cancer — Preguntas Frecuentes
Preguntas comunes de pacientes internacionales sobre el tratamiento en Cuba.
CIMAvax-EGF® is a therapeutic cancer vaccine developed in Cuba that stimulates the immune system to produce antibodies against epidermal growth factor (EGF), a protein that lung cancer cells need to grow. By neutralizing EGF, the vaccine helps slow tumor growth and has shown prolonged tumor stabilization in clinical studies.
Historias de Pacientes: Lung Cancer
Condiciones Relacionadas
Usamos cookies para mejorar su experiencia y analizar el tráfico. Al continuar, acepta nuestro uso de cookies. Política de Privacidad